Early application of IFNγ mediated the persistence of HBV in an HBV mouse model

Antiviral Res. 2024 May:225:105872. doi: 10.1016/j.antiviral.2024.105872. Epub 2024 Mar 30.

Abstract

The antiviral activity of interferon gamma (IFNγ) against hepatitis B virus (HBV) was demonstrated both in vivo and in vitro in a previous study. IFNγ can suppress HBV replication by accelerating the decay of replication-competent nucleocapsids of HBV. However, in this study, we found that the direct application of the mouse IFNγ (mIFNγ) expression plasmid to the liver of an HBV hydrodynamic injection (HI) mouse model led to the persistence of HBV, as indicated by sustained HBsAg and HBeAg levels in the serum as well as an increased percentage of the HBsAg positive mice, whereas the level of HBV DNA in the serum and the expression of HBcAg in the liver were inhibited at the early stage after HI. Meanwhile, we found that the productions of both HBcAb and HBsAb were suppressed after the application of mIFNγ. In addition, we found that HBV could be effectively inhibited in mice immunized with HBsAg expression plasmid before the application of mIFNγ. Furthermore, mIFNγ showed antiviral effect and promoted the production of HBsAb when the mice subjected to the core-null HBV plasmid. These results indicate that the application of mIFNγ in the HBV HI mouse model, the mice showed defective HBcAg-specific immunity that impeded the production of HBcAb and HBsAb, finally allowing the persistence of the virus. Moreover, IFNγ-induced negative immune regulatory factors also play an important role in virus persistence.

Keywords: HBV; Hydrodynamic injection; IFNγ; Immunoregulation; Mouse model.

MeSH terms

  • Animals
  • Antiviral Agents / pharmacology
  • Hepatitis B Antibodies
  • Hepatitis B Core Antigens / genetics
  • Hepatitis B Surface Antigens
  • Hepatitis B virus*
  • Hepatitis B*
  • Interferon-gamma / metabolism
  • Liver
  • Mice
  • Virus Replication

Substances

  • Interferon-gamma
  • Hepatitis B Core Antigens
  • Hepatitis B Surface Antigens
  • Hepatitis B Antibodies
  • Antiviral Agents